Should I buy Gilead Sciences (GILD) stock or is it too late?

Gilead Sciences · Health Care · price $149

See the full Gilead Sciences (GILD) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Morgan Stanley — 69% of its targets hit on this sector (825 calls tested). It aims for $165 (+11 %), call made on July 28, 2026, maturing on July 28, 2027 (31 d ago).

The 5 reliable analysts $156+4.8 %

The 6 other firms $160+7.5 %

How to read it: the 5 reliable firms are not filtered by optimism — 3 aim above the price, 2 below, hence their $156 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Gilead Sciences

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
UBS	89 %	+61.1 %	9	$155 +4%
JP Morgan	90 %	+35.0 %	10	$150 +1%
BMO Capital	79 %	+28.9 %	14	$130 -13%
Wells Fargo	86 %	+26.0 %	7	$165 +11%
Morgan Stanley	69 %	+23.1 %	13	$165 +11%
Barclays	50 %	+21.0 %	10	$145 -3%
Citigroup	44 %	+8.9 %	9	$165 +11%
RBC Capital	60 %	+6.5 %	10	$123 -17%

In short — Should you invest in Gilead Sciences? Is it too late, still worth it? Analysts are fairly positive (73% buy, median target $156, i.e. +5%), and the most reliable on GILD targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

73% of analysts rate it a buy (Buy consensus, 11 ratings) — a sign of market conviction.
The most reliable firm on GILD, JP Morgan (90% hit rate, 10 scored calls), targets $150 (call made on October 31, 2025, maturing on October 31, 2026) (+1%) in its most recent call, and $145 (call made on September 16, 2025, maturing on September 16, 2026) (-3%) in the one coming due soonest.
Pays a dividend (2.6% yield), raised for 10 years — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 11 ratings, 3 are neutral.
Limited upside: the median target is only +5% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on GILD

Median target $156 (+5%) · 11 ratings · Buy consensus

Strong Buy00%

Buy873%

Hold327%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Gilead Sciences now?

We won't decide for you. The facts: 73% of analysts rate it a buy, median target $156 (+5%), and JP Morgan (most reliable on GILD, 90%) targets $150. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Gilead Sciences?

Not according to analysts: the median target ($156) is still +5% above the current price ($149) (most reliable on GILD: JP Morgan, 90%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Gilead Sciences still worth investing in?

It depends on the gap between the price ($149) and its estimated value: analysts target $156 on median (+5%), with 73% buys (most reliable on GILD: JP Morgan, 90%). Cross-check with their real reliability on GILD and the cautions above. Information, not advice.

What's the main risk in buying GILD?

The consensus is not unanimous: of 11 ratings, 3 are neutral.

→ Go deeper: the full Gilead Sciences profile (consensus, analyst reliability, price target, performance).